Literature DB >> 32429727

Dengue vaccines: the road to failure or to success?

Stanley A Plotkin1,2.   

Abstract

A licensed vaccine against dengue was shown to enhance disease under some circumstances, even though it protected most vaccinees. We discuss the implication of these results for the future of dengue vaccines.

Keywords:  Dengue; correlate of protection; enhancement

Year:  2020        PMID： 32429727      PMCID： PMC7733934          DOI： 10.1080/21645515.2020.1733367

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN： 2164-5515            Impact factor:   3.452


  23 in total

1.  Dengue type 1 viruses circulating in humans are highly infectious and poorly neutralized by human antibodies.

Authors:  Rajendra Raut; Kizzmekia S Corbett; Rashika N Tennekoon; Sunil Premawansa; Ananda Wijewickrama; Gayani Premawansa; Piotr Mieczkowski; Claudia Rückert; Gregory D Ebel; Aruna D De Silva; Aravinda M de Silva
Journal:  Proc Natl Acad Sci U S A       Date:  2018-12-05       Impact factor: 11.205

2.  Correcting a public health fiasco: The need for a new vaccine against Lyme disease.

Authors:  Stanley A Plotkin
Journal:  Clin Infect Dis       Date:  2011-02       Impact factor: 9.079

3.  Four-year safety follow-up of the tetravalent dengue vaccine efficacy randomized controlled trials in Asia and Latin America.

Authors:  J L Arredondo-García; S R Hadinegoro; H Reynales; M N Chua; D M Rivera Medina; T Chotpitayasunondh; N H Tran; C C Deseda; D N Wirawan; M Cortés Supelano; C Frago; E Langevin; D Coronel; T Laot; A P Perroud; L Sanchez; M Bonaparte; K Limkittikul; D Chansinghakul; S Gailhardou; F Noriega; T A Wartel; A Bouckenooghe; B Zambrano
Journal:  Clin Microbiol Infect       Date:  2018-02-08       Impact factor: 8.067

Review 4.  Dengue.

Authors:  Annelies Wilder-Smith; Eng-Eong Ooi; Olaf Horstick; Bridget Wills
Journal:  Lancet       Date:  2019-01-26       Impact factor: 79.321

5.  Human CD4+ T Cell Responses to an Attenuated Tetravalent Dengue Vaccine Parallel Those Induced by Natural Infection in Magnitude, HLA Restriction, and Antigen Specificity.

Authors:  Michael A Angelo; Alba Grifoni; Patrick H O'Rourke; John Sidney; Sinu Paul; Bjoern Peters; Aruna D de Silva; Elizabeth Phillips; Simon Mallal; Sean A Diehl; Beth D Kirkpatrick; Stephen S Whitehead; Anna P Durbin; Alessandro Sette; Daniela Weiskopf
Journal:  J Virol       Date:  2017-02-14       Impact factor: 5.103

Review 6.  Challenges to Developing a Rotavirus Vaccine.

Authors:  Paul A Offit
Journal:  Viral Immunol       Date:  2017-12-21       Impact factor: 2.257

7.  In a randomized trial, the live attenuated tetravalent dengue vaccine TV003 is well-tolerated and highly immunogenic in subjects with flavivirus exposure prior to vaccination.

Authors:  Stephen S Whitehead; Anna P Durbin; Kristen K Pierce; Dan Elwood; Benjamin D McElvany; Ellen A Fraser; Marya P Carmolli; Cecilia M Tibery; Noreen A Hynes; Matthew Jo; Janece M Lovchik; Catherine J Larsson; Elena A Doty; Dorothy M Dickson; Catherine J Luke; Kanta Subbarao; Sean A Diehl; Beth D Kirkpatrick
Journal:  PLoS Negl Trop Dis       Date:  2017-05-08

8.  Immunogenicity and safety of a dengue vaccine given as a booster in Singapore: a randomized Phase II, placebo-controlled trial evaluating its effects 5-6 years after completion of the primary series.

Authors:  Juliana Park; Sophia Archuleta; May-Lin Helen Oh; Lynette Pei-Chi Shek; Jing Jin; Matthew Bonaparte; Carina Fargo; Alain Bouckenooghe
Journal:  Hum Vaccin Immunother       Date:  2019-11-05       Impact factor: 3.452

Review 9.  Considering Genomic and Immunological Correlates of Protection for a Dengue Intervention.

Authors:  Joshua Blight; Eduardo Alves; Arturo Reyes-Sandoval
Journal:  Vaccines (Basel)       Date:  2019-12-03

Review 10.  A review of Dengvaxia®: development to deployment.

Authors:  Stephen J Thomas; In-Kyu Yoon
Journal:  Hum Vaccin Immunother       Date:  2019-10-07       Impact factor: 3.452
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.